The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Role of Advanced Glycation End Products in Carcinogenesis and their Therapeutic Implications
Open accessAbstract
Aging is one of the biggest risk factors for the major prevalent diseases such as cardiovascular diseases, neurodegeneration and cancer, but due to the complex and multifactorial nature of the aging process, the molecular mechanisms underlying age-related diseases are not yet fully understood. Research has been intensive in the last years aiming to characterize the pathophysiology of aging and develop therapies to fight age-related diseases. In this context advanced glycation end products (AGEs) have received attention. AGEs, when accumulated in tissues, significantly increase the level of inflammation in the body which has long been associated with the development of cancer. Here we discuss the classical settings promoting AGE formation, as well as reduction strategies, occurrence and relevance of AGEs in cancer tissues and the role of AGE-interaction with the receptor for advanced glycation end products (RAGE) in cancer initiation and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Advanced glycation end-products: A review
Singh, R., Barden, A., Mori, T., & Beilin, L. (2001) · Diabetologia · doi:10.1007/s001250051591 · Cited by 2,597
Advanced Glycation End Products and Diabetic Complications
Singh, V. P., Bali, A., Singh, N., & Jaggi, A. S. (2014) · The Korean Journal of Physiology & Pharmacology · doi:10.4196/kjpp.2014.18.1.1 · Cited by 1,518
Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.213 · Cited by 1,434
Advanced protein glycosylation in diabetes and aging
Brownlee, M. D. (1995) · Annual Review of Medicine · doi:10.1146/annurev.med.46.1.223 · Cited by 1,312
Yan, S. D., Schmidt, A. M., Anderson, G. M., Zhang, J., Brett, J., Zou, Y. S., Pinsky, D., & Stern, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36966-1 · Cited by 1,306
Advanced glycation end products in foods and a practical guide to their reduction in the diet
Uribarri, J., Woodruff, S., Goodman, S., Cai, W., Chen, X., Pyzik, R., Yong, A., Striker, G. E., & Vlassara, H. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2010.03.018 · Cited by 1,289
Wolff, S. P., & Dean, R. T. (1987) · Biochemical Journal · doi:10.1042/bj2450243 · Cited by 1,271
Research works printed but not linked: 3
- Andres R, Pozefsky T, Swerdloff RS, Tobin JD.
- Namiki M.
- Uribarri J, Woodruff S, Goodman S.
Cited by
Redox Signaling and Advanced Glycation Endproducts (AGEs) in Diet-Related Diseases
Cepas, V., Collino, M., Mayo, J. C., & Sainz, R. M. (2020) · Antioxidants · doi:10.3390/antiox9020142 · Cited by 202
Ramteke, P. L., Deb, A., Shepal, V., & Bhat, M. K. (2019) · Cancers · doi:10.3390/cancers11091402 · Cited by 175
“Avoiding sweetened foods and drinks is often recommended for inhibiting glycation product formation and accumulation, thereby highlighting the role of hyperglycemia in DNA damage [24].”
BackgroundA Role for Advanced Glycation End Products in Molecular Ageing
Zgutka, K., Tkacz, M., Tomasiak, P., & Tarnowski, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129881 · Cited by 173
Toxicity of advanced glycation end products (Review)
Kuzan, A. (2021) · Biomedical Reports · doi:10.3892/br.2021.1422 · Cited by 151
“Other types of cancer CML, CEL, and AGEs, via binding to RAGEs, result in sustained (17,18)”
Yap, K. M., Sekar, M., Fuloria, S., Wu, Y. S., Gan, S. H., Rani, N. N. I. M., Subramaniyan, V., Kokare, C., Lum, P. T., Begum, M. Y., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s328135 · Cited by 131
“Bombesin (BBN; a 14-amino acid peptide) is a natural ligand for gastrin-releasing peptide receptor, which is a G-protein coupled receptor that is overexpressed in various cancers, including BC.274 The same research group thus further conjugated EGCG-SLNs with BBN to achieve active BC cell targeting.275 In the study, i…”
BackgroundInfluential
Metadata
- Authors
- Schröter, D., & Höhn, A.
- Affiliations
- German Institute of Human Nutrition (DE)
- Corresponding author
- Höhn, Annika
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2019-03-29
- Volume
- 24
- Issue
- 44
- Pages
- 5245-5251
- ISSN
- 1381-6128 (ISSN-L)
- PMC
- PMC6635609
- OpenAlex
- W2913046669
- Cited by
- 126
- References
- 101
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 20 · 2023: 24 · 2022: 21 · 2021: 22 · 2020: 10 · 2019: 5
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Current Pharmaceutical Design (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- German Ministry of Education and Research (82DZD00302)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Life Sciences › Agricultural and Biological Sciences › Food Science › Potato Plant Research
- Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
- Keywords
- advanced glycation end products, carcinogenesis, receptor for advanced glycation end products, RAGE, aging, inflammation, AGE formation, tumor progression, tumor initiation, age-related diseases
- MeSH terms
- Receptor for Advanced Glycation End Products, Animals, Humans, Inflammation, Neoplasms, Glycation End Products, Advanced, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Advanced Glycation End Products in Carcinogenesis and their Therapeutic Implications. https://app.cochat.ai/papers/10.2174/1381612825666190130145549
- The paper
- Schröter, D., & Höhn, A. (2019). Role of Advanced Glycation End Products in Carcinogenesis and their Therapeutic Implications. Current Pharmaceutical Design. https://doi.org/10.2174/1381612825666190130145549
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.